MAGEA4 and synovial sarcoma: A phase 2 clinical trial study (SPEARHEAD-1) evaluated afamitresgene autoleucel (afami-cel), a T-cell therapy targeting MAGE-A4, in patients with advanced synovial sarcoma or myxoid round cell liposarcoma.